The National Liberty Museum honored Stephen and Sandra Sheller as “2017 Heroes of Liberty” at the 18th Annual Glass Auction & Gala held on October 7, 2017 at the Sheraton Philadelphia Downtown Hotel.

Stephen and Sandra Sheller joined Councilman Domb and the staff of Jefferson University Hospital’s Maternal Addiction Treatment Education and Research (MATER) project as they cut the ribbon in the grand opening housewarming of My

Risperdal litigation in Philadelphia courts have increased significantly this year and the trend is likely to continue. Mass torts against Janssen, a Johnson & Johnson subsidiary, over it’s antipsychotic drug Risperdal has nearly

In 1984 a federal jury in San Francisco found Dow Corning’s breast implants were “defectively designed and manufactured.” Maria Stern was awarded $1.7 M after internal corporate memos and studies show that Dow

In ‘For Plaintiffs Bar, Taking on J&J Means Battling a Shadow Foe,’ Law.com’s Amanda Bronstad reports on the “intimate relationship” between Johnson & Johnson (J&J) and the U.S. Chamber of Commerce (the Chamber). The U.S. Chamber

A new type of lymphoma called breast implant-associated anapestic large-cell lymphoma has medical authorities finally agreeing that the prosthetics can cause disease. The first recognized case was in 1997, however a warning from

Sheller PC’s $70 Million Risperdal win hits #1 on the Top 50 Verdicts in Pennsylvania in 2016. In the case A.Y., Pro Ami v. Janssen Pharmaceuticals, Inc., a jury found for an autistic Tennessee boy

Stephen A. Sheller, who has served on the board of trustees of Drexel University since 2003 and on Drexel’s Thomas R. Kline School of Law advisory board, will receive an honorary degree at

Sheller PC is currently representing multiple victims nationwide injured by IVC filters. Below are just a few.  Currently 3,500 IVC Filter lawsuits are pending in the U.S. A Texas man will have to live

Patients with type 2 diabetes taking Johnson & Johnson’s drug Invokana are twice as likely to have a leg and foot amputation than patients given a placebo, two clinical trial show. The FDA